Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Ron Bentsur is Chairman & CEO at Nuvectis Pharma. OQRO lists 2 transactions filed with the SEC under this name, the latest on Dec 26, 2024, each linked to the official Form 4.
Chairman & CEO
Disclosures on record
2
Companies involved
1
2 buys, median +68.3 pts vs S&P 500, beat it 2 of 2 times.
Average +68.3 pts vs S&P 500. Each buy is one disclosure of open-market purchases in one company on one filing date, filed Nov 18, 2024 to Dec 26, 2024, measured from the first close after the filing. Past results, not a forecast.
2 purchases disclosed; 100% of the 2 measured at 90 days finished ahead of the index.
Not ranked: fewer than 10 purchases measured at 90 days. The middle of the 83 ranked insiders is −6.8 pts (median, against the S&P 500).
Nuvectis PharmaNVCT
2 disclosures · Nov 2024 – Dec 2024 · 2 bought
Dec 24, 2024Bought~$21Kdisclosed Dec 26
DetailsOfficial recordNov 15, 2024Bought~$98Kdisclosed Nov 18
DetailsEqual weight counts every purchase once; by size counts it for its disclosed dollars. Both are measured from the first close after it was reported. Past results describe the past, not a forecast. How this is measured · Leaderboard
As of the latest filing on , Ron Bentsur reported holding 3,270,924 shares of Nuvectis Pharma (NVCT), worth about $64.9M at the last close of $20 (Nov 19, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Nuvectis Pharma NVCT | 3,270,924 | 3.27M direct | $20 | $64.9M | Dec 24, 2024 |
Is this Ron Bentsur’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Ron Bentsur bought shares on the open market in 2022, 2023 and 2024, and has not bought since 2024 across 2 companies. Sales in 3 of the 7 years since 2020.
Ron Bentsur reported 76 open-market purchases and 28 sales since 2020; purchases in 3 different years, most recently 2024.
| Year | Bought | Sold |
|---|---|---|
| 2024 | $197K5×5 trades | — |
| 2023 | $170K27×27 trades | — |
| 2022 | $2.1M44×44 trades | $261K1×1 trade |
| 2021 | — | $699K5×5 trades |
| 2020 | — | $549K22×22 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Dec 24, 2024, Ron Bentsur reported holding 3,270,924 shares of Nuvectis Pharma (NVCT). At the last close of $20 on Nov 19, 2026, that is about $64.9M. This is the stake disclosed in filings, not a net worth.
No public filing gives Ron Bentsur's net worth. What SEC Form 4 shows is the stock stake: 3,270,924 shares of Nuvectis Pharma (NVCT), about $64.9M at the last close. Cash, other investments, property, debts and unexercised options are not in these filings, so the real figure can be much higher or lower.
Ron Bentsur bought shares on the open market in 2022, 2023 and 2024, and has not bought since 2024 across 2 companies. Sales in 3 of the 7 years since 2020.
In SEC filings since 2020: the latest open-market purchase is from 2024; the latest open-market sale is from 2022.
2 companies: Nuvectis Pharma (NVCT, 2022–2024), Beyond Air (XAIR, 2020–2023).
Ron Bentsur reported 75 open-market purchases and 0 sales here, 2022 to 2024.
Ron Bentsur reported 1 open-market purchase and 28 sales here, 2020 to 2023.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.